Multimodality Imaging and Immune-Related Adverse Events During Immune Checkpoint Inhibitors Treatment: Where Do We...

Area of Science:

• Cardio-oncology
• Immunotherapy
• Cardiovascular Medicine

Background:

• Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, enhancing patient survival rates.
• However, ICIs can induce immune-related adverse events (irAEs), including potentially fatal cardiotoxicity.
• Cardiovascular complications represent a significant challenge in patients receiving immunotherapy.

Purpose of the Study:

• To review the current evidence on immune checkpoint inhibitor-induced cardiotoxicity.
• To highlight the critical role of cardiovascular imaging in managing these adverse events.
• To provide insights for optimizing clinical strategies in immunotherapy patients.

Main Methods:

• Systematic review of current scientific literature.
• Synthesis of evidence regarding ICI-related cardiotoxicity.
• Analysis of the utility of cardiovascular imaging modalities.

Main Results:

• Cardiotoxicity is a serious, albeit rare, complication of ICIs.
• Cardiovascular imaging is essential for early diagnosis and monitoring of ICI-induced cardiotoxicity.
• Tailored imaging strategies are key to effective management.

Conclusions:

• Early and precise cardiovascular imaging is vital for managing ICI-induced cardiotoxicity.
• Integrating imaging into clinical practice can improve patient outcomes.
• Further research is needed to refine management protocols for immunotherapy-related cardiac complications.